Meprednisone

Summary

Meprednisone (CHEMBL1201148) is an approved small molecule (ATC H02AB15); indicated across 1 condition including melanoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: H02AB15
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 372.5 Da · C22H28O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201148
Name	Meprednisone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5284587
ATC	H02AB15
Molecular formula	C22H28O5
Molecular weight	372.5
InChIKey	PIDANAQULIKBQS-RNUIGHNZSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C

IUPAC name: (8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione

Also known as: Betapar, Meprednisona, Meprednisone, NSC-527579, SCH 4358, SCH-4358, MEPREDNISONE, SID170465165, SID144207161, Betapar (Meprednisone)

Patent coverage: 2,765 distinct patent families (10,740 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	2	MONDO:0005105	EFO:0000756

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00623766	PHASE2	COMPLETED	Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).